- Home
- ALXO vs IBG Comparison
ALXO vs IBG Comparison
Compare ALXO & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- IBG
- Stock Information
- Founded
- ALXO 2015
- IBG 2018
- Country
- ALXO United States
- IBG Australia
- Employees
- ALXO N/A
- IBG N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- IBG Beverages (Production/Distribution)
- Sector
- ALXO Health Care
- IBG Consumer Staples
- Exchange
- ALXO Nasdaq
- IBG Nasdaq
- Market Cap
- ALXO 93.7M
- IBG 75.7M
- IPO Year
- ALXO 2020
- IBG 2024
- Fundamental
- Price
- ALXO $1.26
- IBG $2.48
- Analyst Decision
- ALXO Strong Buy
- IBG Strong Buy
- Analyst Count
- ALXO 6
- IBG 1
- Target Price
- ALXO $3.30
- IBG N/A
- AVG Volume (30 Days)
- ALXO 424.8K
- IBG 1.3M
- Earning Date
- ALXO 11-07-2025
- IBG 11-15-2025
- Dividend Yield
- ALXO N/A
- IBG N/A
- EPS Growth
- ALXO N/A
- IBG N/A
- EPS
- ALXO N/A
- IBG N/A
- Revenue
- ALXO N/A
- IBG $2,931,243.00
- Revenue This Year
- ALXO N/A
- IBG N/A
- Revenue Next Year
- ALXO N/A
- IBG N/A
- P/E Ratio
- ALXO N/A
- IBG N/A
- Revenue Growth
- ALXO N/A
- IBG N/A
- 52 Week Low
- ALXO $0.40
- IBG $1.48
- 52 Week High
- ALXO $2.27
- IBG $9.85
- Technical
- Relative Strength Index (RSI)
- ALXO 38.76
- IBG 41.51
- Support Level
- ALXO $1.49
- IBG $3.25
- Resistance Level
- ALXO $1.64
- IBG $4.10
- Average True Range (ATR)
- ALXO 0.14
- IBG 0.37
- MACD
- ALXO -0.05
- IBG -0.22
- Stochastic Oscillator
- ALXO 4.13
- IBG 0.00
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.